NRG Oncology

Advancing cancer research, improving lives.

[NRG Oncology @NRGonc]

Registration is now OPEN for the NRG Oncology Summer Meeting #NRG2026. Join us in Denver 🌄 from July 16-18, 2026 (select virtual sessions held July 10-17). Register soon to avoid the late registration fee! ↪️https://t.co/v6hrkkygi0

[NRG Oncology @NRGonc]

The June issue of FORTE Fridays is now available. This month, we're highlighting the upcoming Amendment 9 updates, consent withdrawal process, and the FORTE Workshop at #NRG2026. Read it here ➡️https://t.co/kasjGb0BUQ @FORTEStudy

[NRG Oncology @NRGonc]

June is #UterineCancerAwarenessMonth. Endometrial cancer is the most common type of #uterinecancer. NRG-GY035 is testing the addition of antiangiogenic drug to chemotherapy combined with immunotherapy for pMMR, TP53 mutated #endometrialcancer. Learn more: https://t.co/m9PmnKo0cw

[NRG Oncology @NRGonc]

June is #CancerSurvivorsMonth, a time to honor cancer survivors whose courage & resilience inspire us every day. Their experiences underscore the importance of continued #clinicaltrial research to improve outcomes & quality of life for patients now & in the future.

[PRIMR @PRIMR_MED]

@ASCO fuels next-gen therapies.

On Day 5 of #ASCO26, we're featuring the SAMURAI trial, testing stereotactic ablative RT + immunotherapy in unresected metastatic RCC to improve outcomes.

Watch the IRB-approved video:
https://t.co/v0tii14xfg

@NRGonc @whallradonc @DrRanaMcKay

[NRG Oncology @NRGonc]

Premenopausal pts w/ER+/HER2- #breastcancer who remain at high risk for recurrence may benefit from intensified systemic therapy strategies. Yesterday at #ASCO26, Dr. Mamounas discussed NRG-BR009 OFSET, a study evaluating the addition of chemotherapy to OFS + endocrine therapy.

[NRG Oncology @NRGonc]

@jamecancerdoc @ASCOPost @ASCO @caraglynn01 Congratulations, Dr. Abraham! 👏🎉

[NRG Oncology @NRGonc]

1 WEEK AWAY - REGISTER for our NRG-GU015 "ARCHER" site webinar discussing the study assessments for the trial studying shorter duration RT for patients receiving chemotherapy for bladder cancer. This webinar will be June 9th at 1:00PM ET. Register at https://t.co/oiS6Z4RrP2

[Ying Liu @YingLiu88]

Very exciting that we have NRG studies GY035 for endometrial cancer, GY036 for ovarian cancer, and GY037 for cervical cancer, all open and enrolling! Great opportunities to advance precision care in GYN cancers for our patients. #asco2026 @NRGonc

[NRG Oncology @NRGonc]

NRG Oncology Weekly Broadcast for June 1, 2026: https://t.co/DjzGzCR7xu

[Ying Liu @YingLiu88]

So privileged to serve as study chair for this first pragmatic and streamlined phase 3 trial in #ovariancancer looking to de-escalate PARPi maintenance. Thanks to all our patients and sites for participating. Let’s keep the momentum going! @NRGonc @TeamOvary_MSK @MSKCancerCenter

[NRG Oncology @NRGonc]

Now enrolling,NRG-BR009/OFSET is evaluating whether adding chemo to ovarian function suppression + endocrine tx can improve outcomes compared to standard hormonal treatment alone. Dr. Terry Mamounas discusses the trial during a poster session at #ASCO26 today. @AdventHealth

[Memorial Sloan Kettering Cancer Center @MSKCancerCenter]

Happening NOW at #ASCO26 ⬇️

[NRG Oncology @NRGonc]

Start off your #ASCO26 Monday morning with two NRG Oncology #GynecologicCancer trials highlighted during poster sessions↪️NRG-GY036 with Dr. Ying Liu @YingLiu88 and NRG-GY037 with Dr. Jyoti Mayadev.
@MSKCancerCenter @UCSDHealth

[Stephen Chun @StephenChunMD]

Arguably the most important study for locally-advanced endometrial cancer in decades (since carbo/taxol). Listen to @NRGonc Podcast on life saving impact of @Merck pembrolizumab in GY018 w @UCSDCancer @rne_md. Many women’s lives will be saved! @lauren_henke @GOG

[UT MD Anderson @UTMDAnderson]

Can a less invasive approach improve quality of life for patients with early-stage oral cavity cancer while maintaining cancer outcomes?

The phase II/III NRG-HN006 trial is evaluating sentinel lymph node biopsy as an alternative to elective neck dissection. Presented by Dr. Stephen Lai at #ASCO26. @NRGonc #EndCancer 5/5

[Jeff Ryckman @jryckman3]

Fantastic podcast on a potentially practice-changing study evaluating doublet therapy for patients who meet high-risk, but not very-high-risk, criteria.

Congrats to @krishnan_patel and co-authors. Looking forward to the full publication! #PCSM #ASCO26 #OncTwitter

[PRIMR @PRIMR_MED]

@ASCO is redefining treatment standards.

On Day 3 of #ASCO26, we’re featuring ARCHER, testing shorter SBRT vs standard radiation with chemo for bladder cancer, protecting quality of life.

Watch the IRB-approved video:
https://t.co/8udYyvglc9

@NRGonc @HimanshuNagarMD

[NSABP Foundation @NSABPFoundation]

Surrounded by some of the brightest minds and strongest leaders in oncology at #ASCO26, our NSABP team is proud to be a part of the meaningful progress in cancer research.

[NRG Oncology @NRGonc]

Tomorrow at #ASCO26, Dr. Rastogi discusses legacy NSABP B-28 study during a poster session. B-28 was a randomized trial comparing the worth of paclitaxel following doxorubicin/ cyclophosphamide in patients with #breastcancer and who had positive axillary nodes. @NSABPFoundation

[NRG Oncology @NRGonc]

NRG research in #prostatecancer continues at #ASCO26 today with the poster session for NRG/RTOG 0521. Sebastian Medina discusses the spatial transcriptomics-guided pathology biomarker as a predictor of adjuvant docetaxel in high-risk localized prostate cancer. @WinshipAtEmory